{
    "xml": "<topic id=\"PHP5944\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/filgrastim\" basename=\"filgrastim\" title=\"FILGRASTIM\">\n<title>FILGRASTIM</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_565\" namespace=\"/interactions/list-of-drug-interactions/filgrastim\">Filgrastim</xref>\n</p>\n<data name=\"vtmid\">108965009</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_857996914\" title=\"Granulocyte-colony stimulating factors\">Granulocyte-colony stimulating factors</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34593\" title=\"GRANULOCYTE-COLONY STIMULATING FACTORS\" namespace=\"/drug-classes/granulocyte-colony-stimulating-factors\">GRANULOCYTE-COLONY STIMULATING FACTORS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n<p outputclass=\"synonyms\">Recombinant human granulocyte-colony stimulating factor, G-CSF</p>\r\n</body>\n<topic id=\"PHP50421\" outputclass=\"indicationsAndDose\" rev=\"1.35\" parent=\"/drugs/filgrastim\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Reduction in duration of neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy for malignancy (except chronic myeloid leukaemia and myelodysplastic syndromes) (specialist use only)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>5&#8239;micrograms/kg daily until neutrophil count in normal range usually for up to 14 days (up to 38 days in acute myeloid leukaemia), to be started at least 24 hours after cytotoxic chemotherapy and to be administered over 30 minutes if given by intraveous infusion.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Reduction in duration of neutropenia (and associated sequelae) in myeloablative therapy followed by bone-marrow transplantation (specialist use only)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous infusion or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>10&#8239;micrograms/kg daily, to be started at least 24 hours following cytotoxic chemotherapy and within 24 hours of bone-marrow infusion, then adjusted according to neutrophil count&#8212; consult product literature, doses administered over 30 minutes or 24 hours via intravenous route and over 24 hours via subcutaneous route.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Mobilisation of peripheral blood progenitor cells for autologous infusion, used alone (specialist use only)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous infusion or by subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>10&#8239;micrograms/kg daily for 5&#8211;7 days, to be administered by subcutaneous infusion over 24 hours if given.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Mobilisation of peripheral blood progenitor cells for autologous infusion, used following adjunctive myelosuppressive chemotherapy&#8212;to improve yield (specialist use only)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>5&#8239;micrograms/kg daily until neutrophil count in normal range, to be started the day after completing chemotherapy, for timing of leucopheresis, consult product literature.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Mobilisation of peripheral blood progenitor cells in normal donors for allogeneic infusion (specialist use only)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult 18&#8211;59 years</p>\n<p>10&#8239;micrograms/kg daily for 4&#8211;5 days, for timing of leucopheresis, consult product literature.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Severe congenital neutropenia and history of severe or recurrent infections (distinguish carefully from other haematological disorders) (specialist use only)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 12&#8239;micrograms/kg daily, adjusted according to response, can be given in single or divided doses, consult product literature and local protocol.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Severe cyclic neutropenia, or idiopathic neutropenia and history of severe or recurrent infections (distinguish carefully from other haematological disorders) (specialist use only)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 5&#8239;micrograms/kg daily, adjusted according to response, can be given in single or divided doses, consult product literature and local protocol.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Persistent neutropenia in HIV infection (specialist use only)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 1&#8239;microgram/kg daily, subsequent doses increased as necessary until neutrophil count in normal range, then adjusted to maintain neutrophil count in normal range&#8212;consult product literature; maximum 4&#8239;micrograms/kg per day.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50486\" outputclass=\"contraindications\" rev=\"1.7\" parent=\"/drugs/filgrastim\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Severe congenital neutropenia (Kostmann&#8217;s syndrome) with abnormal cytogenetics</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65238\" outputclass=\"cautions\" rev=\"1.10\" parent=\"/drugs/filgrastim\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Osteoporotic bone disease (monitor bone density if given for more than 6 months)</ph>; <ph outputclass=\"caution\">secondary acute myeloid leukaemia</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50418\" outputclass=\"interactions\" rev=\"1.7\" parent=\"/drugs/filgrastim\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (filgrastim).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50397\" outputclass=\"sideEffects\" rev=\"1.8\" parent=\"/drugs/filgrastim\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Anaemia</ph>; <ph outputclass=\"sideEffect\">dysuria</ph>; <ph outputclass=\"sideEffect\">epistaxis</ph>; <ph outputclass=\"sideEffect\">exacerbation of rheumatoid arthritis</ph>; <ph outputclass=\"sideEffect\">haematuria</ph>; <ph outputclass=\"sideEffect\">hepatomegaly</ph>; <ph outputclass=\"sideEffect\">mucositis</ph>; <ph outputclass=\"sideEffect\">osteoporosis</ph>; <ph outputclass=\"sideEffect\">proteinuria</ph>; <ph outputclass=\"sideEffect\">pseudogout</ph>; <ph outputclass=\"sideEffect\">raised uric acid</ph>; <ph outputclass=\"sideEffect\">splenic enlargement</ph>; <ph outputclass=\"sideEffect\">transient decrease in blood glucose</ph>; <ph outputclass=\"sideEffect\">transient hypotension</ph>; <ph outputclass=\"sideEffect\">urinary abnormalities</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Capillary leak syndrome (including fatal cases)</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Splenic rupture</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50378\" outputclass=\"monitoringRequirements\" parent=\"/drugs/filgrastim\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Regular morphological and cytogenetic bone-marrow examinations recommended in severe congenital neutropenia (possible risk of myelodysplastic syndromes or leukaemia).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65317\" outputclass=\"directionsForAdministration\" rev=\"1.16\" parent=\"/drugs/filgrastim\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>For <i>intravenous infusion</i> (<i>Neupogen</i>\n<tm tmtype=\"reg\"/>); (<i>Nivestim</i>\n<tm tmtype=\"reg\"/>); (<i>Ratiograstim</i>\n<tm tmtype=\"reg\"/>); (<i>Zarzio</i>\n<tm tmtype=\"reg\"/>) give continuously <i>or</i> intermittently <i>in </i>Glucose 5%; for a filgrastim concentration of less than 1&#8239;500&#8239;000&#8239; units/mL (15&#8239;micrograms/mL) albumin solution (human albumin solution) is added to produce a final albumin concentration of 2&#8239;mg/mL; should not be diluted to a filgrastim concentration of less than 200&#8239;000&#8239;units/mL (2&#8239;micrograms/mL) and should not be diluted with sodium chloride solution.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60436\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.10\" parent=\"/drugs/filgrastim\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Products containing filgrastim are not identical and although theoretically there should be no important differences in terms of safety and efficacy, when prescribing biological products it is good practice to use the brand name.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP5944-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/filgrastim\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74623\" title=\"Solution for injection\" namespace=\"/drugs/filgrastim/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78575\" namespace=\"/treatment-summaries/neutropenia\" title=\"Neutropenia\" count=\"5\" rel=\"backlink\">Neutropenia</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_565\" namespace=\"/interactions/list-of-drug-interactions/filgrastim\" title=\"Filgrastim\" count=\"1\" rel=\"link\">Filgrastim</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34593\" namespace=\"/drug-classes/granulocyte-colony-stimulating-factors\" title=\"GRANULOCYTE-COLONY STIMULATING FACTORS\" count=\"1\" rel=\"link\">GRANULOCYTE-COLONY STIMULATING FACTORS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74623\" namespace=\"/drugs/filgrastim/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP5944",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/filgrastim",
    "basename": "filgrastim",
    "title": "FILGRASTIM",
    "interactants": [
        {
            "id": "bnf_int_565",
            "label": "Filgrastim"
        }
    ],
    "vtmid": "108965009",
    "drugClassification": [
        "Granulocyte-colony stimulating factors"
    ],
    "inheritsFromClass": [
        "GRANULOCYTE-COLONY STIMULATING FACTORS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "synonyms": [
        "Recombinant human granulocyte-colony stimulating factor, G-CSF"
    ],
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Reduction in duration of neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy for malignancy (except chronic myeloid leukaemia and myelodysplastic syndromes) (specialist use only)",
                        "html": "Reduction in duration of neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy for malignancy (except chronic myeloid leukaemia and myelodysplastic syndromes) (specialist use only)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection or intravenous infusion"
                    ],
                    "textContent": "By subcutaneous injection or by intravenous infusion",
                    "html": "By subcutaneous injection or by intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "5 micrograms/kg daily until neutrophil count in normal range usually for up to 14 days (up to 38 days in acute myeloid leukaemia), to be started at least 24 hours after cytotoxic chemotherapy and to be administered over 30 minutes if given by intraveous infusion.",
                        "html": "<p>5&#8239;micrograms/kg daily until neutrophil count in normal range usually for up to 14 days (up to 38 days in acute myeloid leukaemia), to be started at least 24 hours after cytotoxic chemotherapy and to be administered over 30 minutes if given by intraveous infusion.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Reduction in duration of neutropenia (and associated sequelae) in myeloablative therapy followed by bone-marrow transplantation (specialist use only)",
                        "html": "Reduction in duration of neutropenia (and associated sequelae) in myeloablative therapy followed by bone-marrow transplantation (specialist use only)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous infusion or intravenous infusion"
                    ],
                    "textContent": "By subcutaneous infusion or by intravenous infusion",
                    "html": "By subcutaneous infusion or by intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "10 micrograms/kg daily, to be started at least 24 hours following cytotoxic chemotherapy and within 24 hours of bone-marrow infusion, then adjusted according to neutrophil count&#8212; consult product literature, doses administered over 30 minutes or 24 hours via intravenous route and over 24 hours via subcutaneous route.",
                        "html": "<p>10&#8239;micrograms/kg daily, to be started at least 24 hours following cytotoxic chemotherapy and within 24 hours of bone-marrow infusion, then adjusted according to neutrophil count&#8212; consult product literature, doses administered over 30 minutes or 24 hours via intravenous route and over 24 hours via subcutaneous route.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Mobilisation of peripheral blood progenitor cells for autologous infusion, used alone (specialist use only)",
                        "html": "Mobilisation of peripheral blood progenitor cells for autologous infusion, used alone (specialist use only)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous infusion or subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous infusion or by subcutaneous injection",
                    "html": "By subcutaneous infusion or by subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "10 micrograms/kg daily for 5&#8211;7 days, to be administered by subcutaneous infusion over 24 hours if given.",
                        "html": "<p>10&#8239;micrograms/kg daily for 5&#8211;7 days, to be administered by subcutaneous infusion over 24 hours if given.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Mobilisation of peripheral blood progenitor cells for autologous infusion, used following adjunctive myelosuppressive chemotherapy&#8212;to improve yield (specialist use only)",
                        "html": "Mobilisation of peripheral blood progenitor cells for autologous infusion, used following adjunctive myelosuppressive chemotherapy&#8212;to improve yield (specialist use only)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "5 micrograms/kg daily until neutrophil count in normal range, to be started the day after completing chemotherapy, for timing of leucopheresis, consult product literature.",
                        "html": "<p>5&#8239;micrograms/kg daily until neutrophil count in normal range, to be started the day after completing chemotherapy, for timing of leucopheresis, consult product literature.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Mobilisation of peripheral blood progenitor cells in normal donors for allogeneic infusion (specialist use only)",
                        "html": "Mobilisation of peripheral blood progenitor cells in normal donors for allogeneic infusion (specialist use only)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "10 micrograms/kg daily for 4&#8211;5 days, for timing of leucopheresis, consult product literature.",
                        "html": "<p>10&#8239;micrograms/kg daily for 4&#8211;5 days, for timing of leucopheresis, consult product literature.</p>",
                        "ageGroup": "18&#8211;59 years"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Severe congenital neutropenia and history of severe or recurrent infections (distinguish carefully from other haematological disorders) (specialist use only)",
                        "html": "Severe congenital neutropenia and history of severe or recurrent infections (distinguish carefully from other haematological disorders) (specialist use only)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 12 micrograms/kg daily, adjusted according to response, can be given in single or divided doses, consult product literature and local protocol.",
                        "html": "<p>Initially 12&#8239;micrograms/kg daily, adjusted according to response, can be given in single or divided doses, consult product literature and local protocol.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Severe cyclic neutropenia, or idiopathic neutropenia and history of severe or recurrent infections (distinguish carefully from other haematological disorders) (specialist use only)",
                        "html": "Severe cyclic neutropenia, or idiopathic neutropenia and history of severe or recurrent infections (distinguish carefully from other haematological disorders) (specialist use only)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 5 micrograms/kg daily, adjusted according to response, can be given in single or divided doses, consult product literature and local protocol.",
                        "html": "<p>Initially 5&#8239;micrograms/kg daily, adjusted according to response, can be given in single or divided doses, consult product literature and local protocol.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Persistent neutropenia in HIV infection (specialist use only)",
                        "html": "Persistent neutropenia in HIV infection (specialist use only)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 1 microgram/kg daily, subsequent doses increased as necessary until neutrophil count in normal range, then adjusted to maintain neutrophil count in normal range&#8212;consult product literature; maximum 4 micrograms/kg per day.",
                        "html": "<p>Initially 1&#8239;microgram/kg daily, subsequent doses increased as necessary until neutrophil count in normal range, then adjusted to maintain neutrophil count in normal range&#8212;consult product literature; maximum 4&#8239;micrograms/kg per day.</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Severe congenital neutropenia (Kostmann&#8217;s syndrome) with abnormal cytogenetics",
                "html": "Severe congenital neutropenia (Kostmann&#8217;s syndrome) with abnormal cytogenetics"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Osteoporotic bone disease (monitor bone density if given for more than 6 months)",
                "html": "Osteoporotic bone disease (monitor bone density if given for more than 6 months)"
            },
            {
                "type": "cautions",
                "textContent": "secondary acute myeloid leukaemia",
                "html": "secondary acute myeloid leukaemia"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (filgrastim).",
                "html": "<p>Appendix 1 (filgrastim).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Anaemia",
                        "html": "Anaemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dysuria",
                        "html": "dysuria",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "epistaxis",
                        "html": "epistaxis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "exacerbation of rheumatoid arthritis",
                        "html": "exacerbation of rheumatoid arthritis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "haematuria",
                        "html": "haematuria",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hepatomegaly",
                        "html": "hepatomegaly",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "mucositis",
                        "html": "mucositis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "osteoporosis",
                        "html": "osteoporosis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "proteinuria",
                        "html": "proteinuria",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "pseudogout",
                        "html": "pseudogout",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "raised uric acid",
                        "html": "raised uric acid",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "splenic enlargement",
                        "html": "splenic enlargement",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "transient decrease in blood glucose",
                        "html": "transient decrease in blood glucose",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "transient hypotension",
                        "html": "transient hypotension",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "urinary abnormalities",
                        "html": "urinary abnormalities",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Capillary leak syndrome (including fatal cases)",
                        "html": "Capillary leak syndrome (including fatal cases)",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Splenic rupture",
                        "html": "Splenic rupture",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ]
            }
        }
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Regular morphological and cytogenetic bone-marrow examinations recommended in severe congenital neutropenia (possible risk of myelodysplastic syndromes or leukaemia).",
                "html": "<p>Regular morphological and cytogenetic bone-marrow examinations recommended in severe congenital neutropenia (possible risk of myelodysplastic syndromes or leukaemia).</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous infusion (Neupogen ); (Nivestim ); (Ratiograstim ); (Zarzio ) give continuously or intermittently in Glucose 5%; for a filgrastim concentration of less than 1 500 000 units/mL (15 micrograms/mL) albumin solution (human albumin solution) is added to produce a final albumin concentration of 2 mg/mL; should not be diluted to a filgrastim concentration of less than 200 000 units/mL (2 micrograms/mL) and should not be diluted with sodium chloride solution.",
                "html": "<p>For <i>intravenous infusion</i> (<i>Neupogen</i>\n<tm tmtype=\"reg\"/>); (<i>Nivestim</i>\n<tm tmtype=\"reg\"/>); (<i>Ratiograstim</i>\n<tm tmtype=\"reg\"/>); (<i>Zarzio</i>\n<tm tmtype=\"reg\"/>) give continuously <i>or</i> intermittently <i>in </i>Glucose 5%; for a filgrastim concentration of less than 1&#8239;500&#8239;000&#8239; units/mL (15&#8239;micrograms/mL) albumin solution (human albumin solution) is added to produce a final albumin concentration of 2&#8239;mg/mL; should not be diluted to a filgrastim concentration of less than 200&#8239;000&#8239;units/mL (2&#8239;micrograms/mL) and should not be diluted with sodium chloride solution.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "Products containing filgrastim are not identical and although theoretically there should be no important differences in terms of safety and efficacy, when prescribing biological products it is good practice to use the brand name.",
                "html": "<p>Products containing filgrastim are not identical and although theoretically there should be no important differences in terms of safety and efficacy, when prescribing biological products it is good practice to use the brand name.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP74623",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78575",
                "label": "Neutropenia",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_565",
                "label": "Filgrastim",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34593",
                "label": "GRANULOCYTE-COLONY STIMULATING FACTORS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP74623",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}